Madrigal press releases are available below. Search them by keyword or browse by date. Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 November 3, 2026 Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates October 27, 2026 Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH October 20, 2026 Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026 October 15, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) October 6, 2026 Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants September 16, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) September 2, 2026 Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference August 20, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) August 12, 2026 Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors August 6, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
November 3, 2026 Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
October 27, 2026 Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
October 20, 2026 Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
October 15, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
October 6, 2026 Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
September 16, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
September 2, 2026 Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
August 20, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
August 6, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
